Study identifier:D9612C00025
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase III, Multicenter, Open-Label Study To Evaluate the Control of Gastric Acid Secretion with Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome For 12 Months
Zollinger-Ellison Syndrome
Phase 3
No
Esomeprazole magnesium (Nexium)
All
25
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.
Location
Location
Gainesville, FL, United States
Location
Philadelphia, PA, United States
Location
Los Angeles, CA, United States
Location
Paris, France
Location
Saint Germain en Laye, France
Location
Clichy, France
Location
Columbus, OH, United States
Location
King of Prussia, PA, United States
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.